# 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

> **NCT03649438** · — · NO_LONGER_AVAILABLE · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Relapsed Neuroblastoma
- Metastatic Pheochromocytoma

## Interventions

- **DRUG:** 131 I-Metaiodobenzylguanidine
- **DRUG:** Potassium Iodide
- **DRUG:** G-csf

## Key facts

- **NCT ID:** NCT03649438
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649438, "131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03649438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*